Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab with or without verteporfin PDT in macular polypoidal choroidal vasculopathy
jRCT1080222105Phase 4
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ranibizumab in polypoidal choroidal vasculopathy (PCV) (2 arms), sponsored by Novartis. Primary endpoint: Primary visual outcome.
02
Drugs
ranibizumab
03
Conditions
polypoidal choroidal vasculopathy (PCV)
Beyond the preview
Go deeper on jRCT1080222105.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222105.